Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy

Sponsor
Ankara Etlik City Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06114758
Collaborator
(none)
75
1
14
5.3

Study Details

Study Description

Brief Summary

Fibroids are the most commonly encountered tumors in the female reproductive system. In patients, fibroids most often lead to abnormal uterine bleeding and the resulting anemia. In some cases, they can cause infertility or habitual abortions. Another complaint caused by fibroids is pain due to pressure and effects on adjacent organs. Very large fibroids can lead to abdominal swelling. Therefore, if a patient becomes symptomatic due to fibroids, myomectomy or, if necessary, hysterectomy is required.

Because fibroids have a significant blood supply, there is a high risk of intraoperative bleeding and related complications. Additionally, the most common complication in these patients after the operation is bleeding. In many of these patients, intraoperative or postoperative blood transfusions are performed. If bleeding cannot be intervened early in these patients, hemodynamic instability, shock, coagulopathy, and, in the final stage, death can occur due to hemorrhage. Therefore, both intraoperative and postoperative bleeding control is of vital importance in patients undergoing myomectomy.

Condition or Disease Intervention/Treatment Phase

Detailed Description

In this study, data of patients admitted with a diagnosis of uterine fibroids to the Department of Obstetrics and Gynecology, Women's Health and Obstetrics (EŞH) between September 1, 2022, and Sempember 1, 2024, who underwent myomectomy (either laparotomic or laparoscopic), will be collected.

The parameters to be examined in the research are as follows:
  1. Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).

  2. Shock indices.

  3. Hemogram and hematocrit values at 6-24 hours postoperatively.

  4. Duration of the surgery.

  5. Adverse effects experienced by the patients.

  6. Additional treatments administered.

  7. Whether blood transfusion was performed or not.

In this study, the G-power analysis program was used to determine the minimum sample size, taking into account a 10% margin of error. According to the analysis results, the minimum number of patients to be included in the study for a total of 75 patients across 3 groups was determined. Statistical analysis of the data obtained in the study will be conducted using the SPSS Statistics 22 software package. A 95% confidence interval will be calculated for each variable, and results will be considered statistically significant for p < 0.05.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
75 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Comparison of the Effectiveness of Rectal Misoprostol and Intravenous Tranexamic Acid in Reducing Intraoperative Bleeding in Patients Undergoing Myomectomy
Actual Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
control group - group 1

Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation). Shock indices. Hemogram and hematocrit values at 6-24 hours postoperatively. Duration of the surgery. Adverse effects experienced by the patients. Additional treatments administered. Whether blood transfusion was performed or not.

intraoperatively admistiration of tranexamic acid (1 gram intravenous) - group 2

Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation). Shock indices. Hemogram and hematocrit values at 6-24 hours postoperatively. Duration of the surgery. Adverse effects experienced by the patients. Additional treatments administered. Whether blood transfusion was performed or not.

Drug: Transamine
1 gram intravenous slow infusion intraoperatively as we start the laparatomy
Other Names:
  • tranexamic acid
  • intraoperatively admistiration of prostoglandin f2 alfa (cytotec 400 microgram rectal)- group 2

    Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation). Shock indices. Hemogram and hematocrit values at 6-24 hours postoperatively. Duration of the surgery. Adverse effects experienced by the patients. Additional treatments administered. Whether blood transfusion was performed or not.

    Drug: Cytotec 200Mcg Tablet
    the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
    Other Names:
  • misoprostol
  • prostoglandin f2α
  • Outcome Measures

    Primary Outcome Measures

    1. Comparison of patients' preoperative and postoperative hemogram levels [24 hours]

      The basal hemogram levels ( gr/dL) of the patients will be compared with the hemogram levels at 6 and 24 hours.

    2. Comparison of patients' preoperative and postoperative hematocrit levels [24 hours]

      The basal hematocrit levels (%) of the patients will be compared with the hematocrit levels at 6 and 24 hours.

    3. Comparison of patients' postoperative shock indices [6 hour]

      postoperative 1st, 2nd, and 6th-hour shock indices (heart rate (beats in minute) / systolic blood pressure(mmHg) ) will be compared

    Secondary Outcome Measures

    1. Comparison of the patients' postoperative heart rate [6 hour]

      Patients postoperative 1st, 2nd, and 6th-hour heart rate (beats in minute) will be compared

    2. Comparison of the patients' postoperative systolic and diastolic blood pressure [6 hour]

      Patients postoperative 1st, 2nd, and 6th-hour systolic and diastolic blood pressure (mmHg) will be compared

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients over 18 years of age

    • Laparotomic myomectomy surgeries

    • Laparoscopic myomectomy surgeries

    Exclusion Criteria:
    • Identifying missing or suspicious data related to the patient

    • Administering both intraoperative and postoperative medications to the patient

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Etlik City Hospital Ankara Turkey

    Sponsors and Collaborators

    • Ankara Etlik City Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tuğba Ağbal, clinical doctor, Ankara Etlik City Hospital
    ClinicalTrials.gov Identifier:
    NCT06114758
    Other Study ID Numbers:
    • AEŞH-EK1-2023-383
    First Posted:
    Nov 2, 2023
    Last Update Posted:
    Nov 2, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Tuğba Ağbal, clinical doctor, Ankara Etlik City Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 2, 2023